Palisade Bio Inc - PALI STOCK NEWS

Palisade Bio (Nasdaq: PALI) announced that data from the pooled analysis of studies LBS-IST-POI-101 and LBS-POI-201-CN will be presented at the SAGES 2022 Annual Meeting. The presentation will cover the incidence and severity of post-surgical intraabdominal adhesions after bowel resection surgery, focusing on the effects of the enteral protease inhibitor LB1148. Notably, LB1148 has previously shown a significant 1.1-day improvement in bowel function recovery. The company's innovative lead drug is progressing towards Phase 3 trials.

Palisade Bio, a clinical stage biopharmaceutical company focused on gastrointestinal therapies, will present at the H.C. Wainwright BIOCONNECT Virtual Conference and Biotech Showcase from January 10-13 and January 10-12, 2022, respectively. Their lead program, LB1148, has demonstrated significant results in a Phase 2 trial, showing a 1.1-day improvement in bowel function recovery post-GI surgery. Presentations will be available through their investor relations website. These events highlight Palisade's commitment to advancing innovative treatments for GI complications.

Palisade Bio has announced the issuance of U.S. Patent No. 11,202,768, enhancing its patent portfolio for LB1148, aimed at treating postoperative ileus and adhesions. The patent, effective December 21, 2021, provides coverage until 2037, supporting ongoing clinical trials. LB1148 has shown promising results in Phase 2 trials, significantly improving bowel function recovery post-surgery. The company continues to seek additional patent protections globally to fortify its intellectual property, with FDA Fast Track Designation already granted for LB1148.

Palisade Bio (NASDAQ: PALI) has announced the European Patent Office (EPO) will publish a patent covering its lead drug, LB1148, on December 22, 2021, offering protection until 2035. This patent strengthens IP protection globally, complementing existing patents in the US and other countries. The company is focused on advancing LB1148 through clinical trials aimed at treating acute and chronic gastrointestinal complications. Previous Phase 2 trials showed LB1148's safety and efficacy, indicating significant improvements in bowel function and reduced ICU stays.

Palisade Bio, Inc. (NASDAQ: PALI) announced the equity grants of options covering 150,000 shares to three new employees under its 2021 Inducement Plan. The grants were made as an inducement for these employees to join the company. Nick McCoy has been appointed as VP of Clinical Operations, bringing extensive experience in conducting clinical studies crucial to Palisade's operations. The options granted will vest over three years, contingent on the employees' continued service. Palisade Bio is advancing therapeutic solutions for gastrointestinal complications and is moving its lead asset, LB1148, towards Phase 3 studies.

Palisade Bio, Inc. (PALI) announced its Q3 2021 financial results and key business updates. The Phase 2 clinical trial showed a significant 1.1-day improvement in GI recovery for patients using LB1148 compared to placebo. A $5.2 million investment from Yuma Regional Medical Center will support LB1148's clinical development. Financially, R&D expenses rose to $624,000, while G&A expenses increased to $2.4 million. As of September 30, 2021, cash and cash equivalents stood at $14.1 million, with outstanding debt of $568,000.

Palisade Bio, Inc. (NASDAQ: PALI) has acquired the NSI-189 asset, a neurogenic compound, through an early exercise option as part of its merger with Seneca Biopharma. This acquisition involves an upfront payment of approximately $400,000, along with potential additional payments of up to $4.5 million based on clinical development milestones. Palisade is focused on developing therapies for gastrointestinal complications, with its lead asset, LB1148, showing promising Phase 2 trial results related to bowel function recovery and reduced hospital stays.

Palisade Bio, Inc. (Nasdaq: PALI) has announced that CEO Tom Hallam, Ph.D. will present at the H.C. Wainwright Global Investment Conference from September 13-15, 2021. The presentation will commence on September 13 at 7:00 AM ET and will be available for investors to view online. Dr. Hallam will also engage in one-on-one meetings during the conference. Palisade Bio is focused on developing therapies for gastrointestinal complications, with its lead asset, LB1148, showing promising results in earlier trials.

Palisade Bio, Inc. (PALI) announced a second quarter business update showcasing positive topline results from a Phase 2 study of LB1148, revealing an accelerated return of bowel function post-surgery. The company entered a worldwide in-licensing agreement with the University of California and received FDA Fast Track Designation for LB1148. Financial results showed R&D expenses decreasing to $314,000 while G&A expenses doubled to $2.4 million. Cash reserves stand at $12.7 million with a debt of $1.1 million, supporting ongoing clinical developments.